Copyright
©The Author(s) 2023.
World J Clin Cases. Jul 26, 2023; 11(21): 5136-5146
Published online Jul 26, 2023. doi: 10.12998/wjcc.v11.i21.5136
Published online Jul 26, 2023. doi: 10.12998/wjcc.v11.i21.5136
Table 3 Laboratory findings in patients with fibroblastic rheumatism with available data
| Laboratory data | Expressed levels | Number of patients with available data (n/N, %) |
| ANAs | + | 3/31 (96.88) |
| - | 28/31 (96.88) | |
| ds-DNA | + | 0/18 (56.25) |
| - | 18/18 (56.25) | |
| ANCA | + | 3/23 (71.88) |
| - | 20/23 (71.88) | |
| Anti-SSB | + | 1/15 (46.88) |
| - | 14/15 (46.88) | |
| Anti-Scl-70 | + | 0/17 (53.13) |
| - | 17/17 (53.13) | |
| Anti-Jo-1 | + | 0/21 (65.63) |
| - | 21/21 (65.63) | |
| C3 | + | 0/13 (40.63) |
| - | 13/13 (40.63) | |
| RF | + | 0/33 (100) |
| - | 33/33 (100) | |
| CRP | + | 4/25 (78.13) |
| - | 21/25 (78.13) |
- Citation: Guo H, Liang Q, Dong C, Zhang Q, Gu ZF. Systematic review of fibroblastic rheumatism: A case report. World J Clin Cases 2023; 11(21): 5136-5146
- URL: https://www.wjgnet.com/2307-8960/full/v11/i21/5136.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i21.5136